IDRI to Present Heat Stable RNA Delivery Technology at NFID Annual Conference on Vaccinology Research

IDRI Scientists Demonstrate vaccine delivery system that is stable for at least 8 months at room temperature and 21 months refrigerated

Seattle – April 22, 2021 – Seattle’s Infectious Disease Research Institute (IDRI) announced today that Emily Voigt, Ph.D., will be presenting next week at the National Foundation for Infectious Diseases’ (NFID) Annual Conference on Vaccinology Research. Dr. Voigt’s presentation, A Thermostable, Flexible RNA Vaccine Delivery Platform for Pandemic Response will focus on the how the global community can achieve broad, equitable COVID-19 vaccine distribution, and how innovative vaccine delivery technologies can strengthen future pandemic vaccination efforts.

“Current RNA-based vaccines show great promise to quickly and effectively address existing and emerging infectious diseases as shown by the two safe and effective RNA vaccines in use against COVID-19 less than one year after the pandemic began,” said Dr. Voigt. “However, one of the biggest ongoing challenges facing these extraordinary new vaccines is the ability to distribute them widely in the face of a pandemic. Extensive and costly cold storage requirements for current RNA vaccines debilitate accessibility even in settings with well-established medical infrastructure – challenges greatly compounded in areas with limited resources. We have developed a vaccine delivery system that can effectively deliver RNA vaccines without the need for cold storage. Our RNA vaccine system maintains stability for at least eight months at room temperature, or years at refrigerated temperatures, enabling for rapid vaccine design, potential stockpiling and rapid deployment even in resource-poor settings.

Dr. Voigt will be presenting on Tuesday, April 27th at 12 pm PST. Interested parties can watch Dr. Voigt’s presentation by registering for the 2021 NFID Annual Conference here.

About the National Foundation for Infectious Diseases:
Founded in 1973, the National Foundation for Infectious Diseases (NFID) is a non-profit 501(c)(3) organization dedicated to educating the public and healthcare professionals about the burden, causes, prevention, diagnosis, and treatment of infectious diseases across the lifespan.

The project presented at the conference has been funded in whole or in part with Federal funds from both the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services under Contract No. 75N93019C00059 and from the Defense Advanced Research Projects Agency under cooperative agreement HR0011-18-2-0001. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health or the Defense Advanced Research Projects Agency.
IDRI is a nonprofit biotech organization located in Seattle, Washington that combines high-quality scientific research with product development and manufacturing capabilities to help combat some of the world’s deadliest diseases, including COVID-19. For nearly three decades, much of IDRI’s work has been focused on creating immune-enhancing technologies that improve the body’s natural response to disease. It is IDRI’s mission to make these technologies widely available at a low cost and to build a world in which every person has access to the tools that harness their immune systems and allow for a long, healthy life free of disease.